SITC 2021 | The role of immunotherapy in endocrine-refractory luminal breast cancer

Hans Wildiers, MD, PhD, University Hospitals Leuven, KU Leuven, Leuven, Belgium, talks on the use of immunotherapy in endocrine-refractory luminal metastatic breast cancer (BC). Currently, chemotherapy is the only treatment strategy for this patient population as there have been no clinical trials demonstrating significant improvements with immune checkpoint inhibitors. The Phase IIb AIPAC trial (NCT02614833) is one of the first studies to report efficacy with immunotherapy in these patients and suggests that treatment with eftilagimod alpha, a soluble LAG-3 protein may be a new effective strategy to target the immune system in endocrine-refractory luminal metastatic BC. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.